Biotechnology

Managing partner Shan Fu says the firm can generate stronger returns through its asset-centric accelerator model.

The firm’s share price has nearly tripled over the past year, driven by steady cash flow, global expansion, and a distinct strategy.

Despite its record scale, the deal’s co-co model highlights both rising ambition and lingering skepticism in a cooling market.

Investors are reassessing de novo drug design as firms close major BD transactions.

Chair Zhao Yan is steering the company away from hype-driven marketing, investing in synthetic biology to rebuild growth and credibility.

After inking an USD 8.4 billion deal with BMS, the founder says Biokin’s next chapter is about efficiency, innovation, and going global.

The company hopes to stand out with Diabegone, a diabetes treatment that lasts longer than competing drugs from companies like Novo Nordisk and Eli Lilly.

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.